Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Apollo Healthcare Corp Warrants (03/01/2022) APHWF

Based in Ontario Canada the Apollo Healthcare Corp Apollo is one of the largest private label personal care product manufacturers in North America developing and manufacturing retailer branded and private label products for major North American retailers. Apollos products are sold in tens of thousands of stores across North America and its customer base spans across major North American grocery drug and mass merchandise retailers users as well as wholesale clubs. In addition to private label Apollo also manufactures products on a contract basis for many of its clients.


OTCPK:APHWF - Post by User

Comment by FinnishFlash8on Aug 18, 2021 9:49am
132 Views
Post# 33722725

RE:RE:RE:RE:RE:RE:Bad time for release.....but not all negative

RE:RE:RE:RE:RE:RE:Bad time for release.....but not all negativeI don't agree. Managements ability didn't drive the revenues up, it was covid. Management can't do much if hand sanitizer and cleaning product sales are declining. What they should do in my opinion, is disclose more information to shareholders. I'd like to know exactly how much did that product recall affect revenue in Q2 and what makes them think that "Demand for product is normalizing to historically elevated levels and is expected to accelerate into fiscal 2022."
<< Previous
Bullboard Posts
Next >>